Discover ten23 health’s expertise in pharmaceutical manufacturing. Here, we share insights into cutting-edge technologies, quality standards, and process innovations that shape the future of drug product development. Explore how our manufacturing approach ensures precision, efficiency, and compliance.
As injectable drug products become increasingly sophisticated, the path from development to commercial manufacturing is becoming harder to manage. Formulation development, analytical testing, manufacturing readiness, regulatory planning and fill-finish activities often involve multiple specialist providers, each responsible for a different piece of the puzzle.
In 2025, the US FDA has approved 46 novel drugs that year. Amongst those, 12 biologics—accounting roughly 25% of total approvals—include antibody-drug conjugates (ADCs), fusion proteins, and both mono- and bispecific monoclonal antibodies. While oncology remained the primary focus for the approved biologics, recent approvals also span a diverse range of therapeutic areas, including pulmonary, cardiovascular, renal, immunology, and neurology.
The article highlights how CMC has become a strategic priority in biotech, especially for sterile drug products. It explains the risks of poor CMC planning and shows how ten23 health enables regulatory, manufacturing, and investor confidence.
Integrated development improves speed, quality, and scalability in drug production. This article highlights how ten23 health streamlines the entire process—from molecule characterization to commercial manufacturing—under one roof.
Pre-filled syringes play a key role in modern biologics. This case study explores how ten23 health resolved formulation challenges to ensure safe and stable drug delivery.
Sterile injectables are increasingly important dosage forms and hence are critical to modern medicine, enabling the safe and effective delivery of life-saving drugs directly into the body.
